Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420322 | 1.00 | LMNA (0.53) | LMNAALDH1A1NLRP3LPAR1LPAR3 | |
| SCHEMBL13538559 | 0.92 | LMNA (0.47) | LMNAALDH1A1NLRP3LPAR1LPAR3 | |
| SCHEMBL23975037 | 0.92 | LMNA (0.47) | LMNAALDH1A1NLRP3LPAR1LPAR3 | |
| SCHEMBL1058293 | 0.90 | LMNA (0.68) | LMNAALDH1A1NLRP3POLB | |
| SCHEMBL30581340 | 0.88 | LMNA (0.50) | LMNALPAR1LPAR3ENPP2POLB | |
| SCHEMBL18309893 | 0.86 | ALDH1A1 (0.47) | LMNAALDH1A1NLRP3LPAR1LPAR3 | |
| SCHEMBL27469061 | 0.86 | LMNA (0.67) | LMNAALDH1A1LPAR1LPAR3ENPP2 | |
| SCHEMBL1759102 | 0.86 | DGKA (0.57) | LMNALPAR1LPAR3ENPP2DGKA | |
| SCHEMBL11749335 | 0.84 | DGKA (0.60) | NLRP3LPAR1LPAR3ENPP2DGKA | |
| SCHEMBL11755305 | 0.84 | DGKA (0.60) | NLRP3LPAR1LPAR3ENPP2DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2009108704-A1 | O-ALKYLATED PI-3 KINASE INHIBITOR PRODRUG COMBINATION | SEMAFORE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7396828-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | LMNA 3669/4885ALDH1A1 4399/4885NLRP3 2905/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | LMNA 3243/4885ALDH1A1 1152/4885NLRP3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.